ARTICLE
14 August 2015

FDA Sends Warning Letter For Kim Kardashian's Instagram Post

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
On Mintz Levin's Health Law and Policy Matters blog, our colleague Joanne Hawana discussed the August 7 Warning Letter sent by FDA to the drug company Duchesnay, Inc...
United States Food, Drugs, Healthcare, Life Sciences

On Mintz Levin's Health Law and Policy Matters blog, our colleague Joanne Hawana discussed the August 7 Warning Letter sent by FDA to the drug company Duchesnay, Inc., after Kim Kardashian praised the company's morning sickness pill Diclegis in an Instagram post.

As described in the blog post, FDA objected to Kardashian's social media post and called it false and misleading because the post failed to include information on significant limitations of the drug, as well as warnings and precautions. Because Kardashian is a paid spokesperson for Diclegis, her Instagram post promoting the drug must follow the same rules as other consumer advertisements for prescription drugs. The social media post was taken down immediately after Duchesnay received the Warning Letter. Read more about it here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More